The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Caplacizumab (Brand name: Cablivi)
- Manufactured by
FDA-approved indication: February 2019, caplacizumab (Cablivi) was approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
National Library of Medicine Drug Information Portal